News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Johns Hopkins University Study Demonstrates 16% Increase in Patient Adherence Using MEMOTEXT and Microsoft HealthVault in the First Randomized Clinical Trial of Its Kind in North America.

6/8/2011 7:36:29 AM

TORONTO, June 8, 2011 /PRNewswire/ - MEMOTEXT presented "The Impact of Automated Dosing Reminders on Medication Adherence Using HealthVault," conducted by Johns Hopkins University and funded by the Microsoft HealthVault Be Well Fund at Mobile Health 2011: What Really Works conference at Stanford University May 4-5, 2011

Preliminary results from the Automated Dosing Reminder Study (ADRS) were also presented at the March 2011 annual meeting of American Glaucoma Society.

Of the 428 participants analyzed thus far, the study showed an increase in adherence from 51 to 67% with daily glaucoma therapy using a MEMOTEXT adherence solution integrated with Microsoft HealthVault. A control group with no intervention showed no change in adherence. The study to be published this year demonstrates efficacy of MEMOTEXT solutions integrated with a personal health record.

"We are extremely pleased with the results of this adherence study." says Amos Adler, president of MEMOTEXT. "Working with Dr. Boland and his team helped make this a success and we are proud of the impact this will have on the future of adherence and people living with glaucoma."

About Glaucoma and Adherence
Glaucoma is the second leading cause of blindness and visual disability worldwide. It's estimated that 2.5 million people in the U.S. are affected by glaucoma, with another 10 million undiagnosed. According to the Glaucoma Research Foundation, there are currently 70 million people worldwide who have been affected by glaucoma. Currently, there is no cure for glaucoma. However, studies have shown that reducing the eye pressure with topical medical therapy, office laser or surgery can prevent occurrence or slow disease progression. The majority of patients diagnosed with glaucoma or ocular hypertension are managed initially with medications. However, despite the availability of effective topical therapies, non-adherence in patients with glaucoma is poor and has been reported between 37-59%.

The leader in speech, social and mobile, medication compliance interventions, MEMOTEXT integrates behavior modification, education and real time support into the everyday lives of patients using technology appropriate to the patient population and condition. MEMOTEXT's ability to learn and remember previously reported knowledge, intentions, and behaviors allow the treatment medication compliance platform to modify content and dialogues for the same individual over time.

SOURCE MEMOTEXT Personalized Adherence Solutions

Read at

comments powered by Disqus